Oncolytics Biotech

Pancreatic Cancer Treatments Poised for Major Advances in 2024

Retrieved on: 
Wednesday, February 7, 2024
Gemcitabine, Pfizer, Bristol Myers Squibb, Investigational New Drug, Trial of the century, Pancreatic cancer, Patient, IND, Drug development, Incidence, ONC, FDA, SMP, TSX, BMY, Messenger, USP1, Woman, Cancer, HRD, Hope, News, Acquisition, Medivir, Oncolytics Biotech, PD-1, Pelareorep, Senior, TGF, Pancreatic Cancer Action Network, Pharmaceutical industry

VANCOUVER, BC, Feb. 7, 2024 /PRNewswire/ -- USA News Group  -  One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer. As well, the deadly disease showed pancreatic cancer rates rising faster among women, causing increased alarm amongst doctors. Thankfully, 2023 also gave a lot of hope in terms of new treatments for the market that could reach US$36 billion by 2036, such as a potential mRNA vaccine, and other developments from biotech companies to lead into 2024, like Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Incyte Corporation (NASDAQ:INCY), Tango Therapeutics, Inc. (NASDAQ:TNGX), RayzeBio, Inc. (NASDAQ:RYZB) and its buyer Bristol-Myers Squibb Company (NYSE:BMY).

Key Points: 
  • VANCOUVER, BC, Feb. 7, 2024 /PRNewswire/ -- USA News Group -  One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer .
  • As well, the deadly disease showed pancreatic cancer rates rising faster among women , causing increased alarm amongst doctors.
  • After closing out 2022 with another fast track designation , Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) and its flagship asset pelareorep continues to make strides in the battle against pancreatic cancer.
  • The results were enough to garner the support of the Pancreatic Cancer Action Network (PanCAN), who selected pelareorep to receive the US$5 million Therapeutic Accelerator Award .

Pancreatic Cancer Treatments Poised for Major Advances in 2024

Retrieved on: 
Wednesday, February 7, 2024
Gemcitabine, Pfizer, Bristol Myers Squibb, Investigational New Drug, Trial of the century, Pancreatic cancer, Patient, IND, Drug development, Incidence, ONC, FDA, SMP, TSX, BMY, Messenger, USP1, Woman, Cancer, HRD, Hope, News, Acquisition, Medivir, Oncolytics Biotech, PD-1, Pelareorep, Senior, TGF, Pancreatic Cancer Action Network, Pharmaceutical industry

VANCOUVER, BC, Feb. 7, 2024 /PRNewswire/ -- USA News Group  -  One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer. As well, the deadly disease showed pancreatic cancer rates rising faster among women, causing increased alarm amongst doctors. Thankfully, 2023 also gave a lot of hope in terms of new treatments for the market that could reach US$36 billion by 2036, such as a potential mRNA vaccine, and other developments from biotech companies to lead into 2024, like Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Incyte Corporation (NASDAQ:INCY), Tango Therapeutics, Inc. (NASDAQ:TNGX), RayzeBio, Inc. (NASDAQ:RYZB) and its buyer Bristol-Myers Squibb Company (NYSE:BMY).

Key Points: 
  • VANCOUVER, BC, Feb. 7, 2024 /PRNewswire/ -- USA News Group -  One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer .
  • As well, the deadly disease showed pancreatic cancer rates rising faster among women , causing increased alarm amongst doctors.
  • After closing out 2022 with another fast track designation , Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) and its flagship asset pelareorep continues to make strides in the battle against pancreatic cancer.
  • The results were enough to garner the support of the Pancreatic Cancer Action Network (PanCAN), who selected pelareorep to receive the US$5 million Therapeutic Accelerator Award .

Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024

Retrieved on: 
Thursday, January 4, 2024
Oncolytics Biotech, AB, PR, FDA, Breast, Roche, Progression-free survival, Health, AIO, Congress, Society, Pancreatic cancer, Cancer, Oncology, Partnering, Paclitaxel, Anal cancer, Conference, ASCO, ONC, Data, Annual general meeting, Patient, RNA, MBC, TIL, ESMO, Tumor microenvironment, Anal canal, Pancreatic Cancer Action Network, Physician, International, FOLFIRINOX, Survival, Christmas and holiday season, Neoplasm, Toxicity, Poster, Fast Track, Gemcitabine, SCCA, SAN, PDAC, Science Translational Medicine, TSX, Pancreas, Pharmaceutical industry

Overview: "2023 was an outstanding year for Oncolytics and the development of pelareorep as a potential cancer therapy.

Key Points: 
  • Overview: "2023 was an outstanding year for Oncolytics and the development of pelareorep as a potential cancer therapy.
  • "We believe our cash balance and strong data, supported by our active business development program, position us well for 2024."
  • Together, these data provide a strong foundation to support advancing pelareorep into registrational-track studies, starting in 2024," continued Dr Coffey.
  • 2024 Outlook: Dr. Coffey concluded by saying, "Looking ahead to 2024, we expect to initiate the first Phase 3 study for pelareorep in pancreatic cancer.

Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024

Retrieved on: 
Thursday, January 4, 2024
Oncolytics Biotech, AB, PR, FDA, Breast, Roche, Progression-free survival, Health, AIO, Congress, Society, Pancreatic cancer, Cancer, Oncology, Partnering, Paclitaxel, Anal cancer, Conference, ASCO, ONC, Data, Annual general meeting, Patient, RNA, MBC, TIL, ESMO, Tumor microenvironment, Anal canal, Pancreatic Cancer Action Network, Physician, International, FOLFIRINOX, Survival, Christmas and holiday season, Neoplasm, Toxicity, Poster, Fast Track, Gemcitabine, SCCA, SAN, PDAC, Science Translational Medicine, TSX, Pancreas, Pharmaceutical industry

Overview: "2023 was an outstanding year for Oncolytics and the development of pelareorep as a potential cancer therapy.

Key Points: 
  • Overview: "2023 was an outstanding year for Oncolytics and the development of pelareorep as a potential cancer therapy.
  • "We believe our cash balance and strong data, supported by our active business development program, position us well for 2024."
  • Together, these data provide a strong foundation to support advancing pelareorep into registrational-track studies, starting in 2024," continued Dr Coffey.
  • 2024 Outlook: Dr. Coffey concluded by saying, "Looking ahead to 2024, we expect to initiate the first Phase 3 study for pelareorep in pancreatic cancer.

Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment

Retrieved on: 
Wednesday, November 29, 2023
Acquisition, Senior, GlobalData, Patient, FTD, Conference, ORR, Cancer, Pancreatic Cancer Action Network, Diagnosis, Oncology, Congress, TSX, Bristol Myers Squibb, Food, Progression-free survival, Oncolytics Biotech, ESMO, Lilly, ECIS, Afatinib, Cabozantinib, Data, Pancreatic cancer, Pelareorep, ONC, Exelixis, CAD, PFS, Drug resistance, Eli Lilly and Company, Gemcitabine, Glomus tumor, Safety, NYSE, Mirati Therapeutics, Disease, Clinical trial, Radiopharmaceutical, Death, FDA, Medical Affairs Bureau, LLY, News, Survival, Pharmaceutical industry

VANCOUVER, BC, Nov. 29, 2023 /PRNewswire/ -- USA News Group  -  According to the European Cancer Information System (ECIS), new cancer cases and deaths are on the rise in the EU. Sadly, this is a trend that's happening in North America too, especially among young people. Perhaps the most concerning are the incidences of pancreatic cancer, which while only being the 4th most common cause of death, remains one of the lowest survival rates among all cancers. Despite the dire odds, several biotech developers are working diligently to find treatments to enhance the chances of those who've been unlucky enough to contract pancreatic cancer. Among the top developers putting out promising results with new treatments are Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Exelixis, Inc. (NASDAQ:EXEL), Mirati Therapeutics, Inc. (NASDAQ:MRTX), Eli Lilly and Company (NYSE:LLY), and POINT Biopharma Global Inc. (NASDAQ:PNT).

Key Points: 
  • Perhaps the most concerning are the incidences of pancreatic cancer, which while only being the 4th most common cause of death, remains one of the lowest survival rates among all cancers.
  • Despite the dire odds, several biotech developers are working diligently to find treatments to enhance the chances of those who've been unlucky enough to contract pancreatic cancer.
  • Late last year, favourable data from trials involving pelareorep in treating pancreatic cancer led to the FDA rewarding it with a Fast Track Designation (FTD) for treating advanced or metastatic pancreatic cancer.
  • By mid-2023, the Pancreatic Cancer Action Network (PanCAN) selected pelareorep for their pivotal Phase 3 trial , called Precision Promise.

Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment

Retrieved on: 
Wednesday, November 29, 2023
Acquisition, Senior, GlobalData, Patient, FTD, Conference, ORR, Cancer, Pancreatic Cancer Action Network, Diagnosis, Oncology, Congress, TSX, Bristol Myers Squibb, Food, Progression-free survival, Oncolytics Biotech, ESMO, Lilly, ECIS, Afatinib, Cabozantinib, Data, Pancreatic cancer, Pelareorep, ONC, Exelixis, CAD, PFS, Drug resistance, Eli Lilly and Company, Gemcitabine, Glomus tumor, Safety, NYSE, Mirati Therapeutics, Disease, Clinical trial, Radiopharmaceutical, Death, FDA, Medical Affairs Bureau, LLY, News, Survival, Pharmaceutical industry

VANCOUVER, BC, Nov. 29, 2023 /PRNewswire/ -- USA News Group  -  According to the European Cancer Information System (ECIS), new cancer cases and deaths are on the rise in the EU. Sadly, this is a trend that's happening in North America too, especially among young people. Perhaps the most concerning are the incidences of pancreatic cancer, which while only being the 4th most common cause of death, remains one of the lowest survival rates among all cancers. Despite the dire odds, several biotech developers are working diligently to find treatments to enhance the chances of those who've been unlucky enough to contract pancreatic cancer. Among the top developers putting out promising results with new treatments are Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Exelixis, Inc. (NASDAQ:EXEL), Mirati Therapeutics, Inc. (NASDAQ:MRTX), Eli Lilly and Company (NYSE:LLY), and POINT Biopharma Global Inc. (NASDAQ:PNT).

Key Points: 
  • Perhaps the most concerning are the incidences of pancreatic cancer, which while only being the 4th most common cause of death, remains one of the lowest survival rates among all cancers.
  • Despite the dire odds, several biotech developers are working diligently to find treatments to enhance the chances of those who've been unlucky enough to contract pancreatic cancer.
  • Late last year, favourable data from trials involving pelareorep in treating pancreatic cancer led to the FDA rewarding it with a Fast Track Designation (FTD) for treating advanced or metastatic pancreatic cancer.
  • By mid-2023, the Pancreatic Cancer Action Network (PanCAN) selected pelareorep for their pivotal Phase 3 trial , called Precision Promise.

Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy

Retrieved on: 
Thursday, November 9, 2023
Patient, SCCA, International, Hope, Gastrointestinal cancer, Conference, Interim, ORR, Anal canal, Anal cancer, ONC, TSX, SAN, Medical imaging, Pharmaceutical industry, Vaccine, Nursing, Oncolytics Biotech, Pelareorep

SAN DIEGO and CALGARY, Alberta, Nov. 9, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the presentation of positive, interim results from the Phase 1/2 GOBLET study evaluating the combination of pelareorep and atezolizumab in second-line patients with unresectable squamous cell carcinoma of the anal canal (SCCA) by Dirk Arnold, M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg, and primary investigator of the GOBLET trial, in an oral presentation at the 2nd International Multidisciplinary Anal Cancer Conference (IMACC) 2023, taking place in Rome, Italy.

Key Points: 
  • "The positive interim data from the anal cancer cohort of the Phase 2 GOBLET study presented today at the IMACC meeting is very exciting for our company and the potential of pelareorep in gastrointestinal cancers.
  • These results met the pre-specified success criteria for the cohort and exceeded the results from historical controls in similar patient populations1-7," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics.
  • GOBLET Study SCCA Patient Overview:
    Patients in the SCCA cohort, presented at IMACC 2023, are undergoing second-line (2L) or later treatment with a combination of pelareorep and atezolizumab.
  • Two or more responses out of the first ten enrolled patients are required to satisfy the Simon two-stage success criteria.

Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy

Retrieved on: 
Thursday, November 9, 2023
Patient, SCCA, International, Hope, Gastrointestinal cancer, Conference, Interim, ORR, Anal canal, Anal cancer, ONC, TSX, SAN, Medical imaging, Pharmaceutical industry, Vaccine, Nursing, Oncolytics Biotech, Pelareorep

SAN DIEGO and CALGARY, Alberta, Nov. 9, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the presentation of positive, interim results from the Phase 1/2 GOBLET study evaluating the combination of pelareorep and atezolizumab in second-line patients with unresectable squamous cell carcinoma of the anal canal (SCCA) by Dirk Arnold, M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg, and primary investigator of the GOBLET trial, in an oral presentation at the 2nd International Multidisciplinary Anal Cancer Conference (IMACC) 2023, taking place in Rome, Italy.

Key Points: 
  • "The positive interim data from the anal cancer cohort of the Phase 2 GOBLET study presented today at the IMACC meeting is very exciting for our company and the potential of pelareorep in gastrointestinal cancers.
  • These results met the pre-specified success criteria for the cohort and exceeded the results from historical controls in similar patient populations1-7," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics.
  • GOBLET Study SCCA Patient Overview:
    Patients in the SCCA cohort, presented at IMACC 2023, are undergoing second-line (2L) or later treatment with a combination of pelareorep and atezolizumab.
  • Two or more responses out of the first ten enrolled patients are required to satisfy the Simon two-stage success criteria.

Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep

Retrieved on: 
Thursday, November 9, 2023
Therapy, Precision, US, Pancreatic Cancer Action Network, Data, FOLFIRINOX, AB, Pancreatic cancer, Hand, Cancer, ONC, Patient, TSX, SAN, Pharmaceutical industry, Oncolytics Biotech, Pelareorep, PDAC

SAN DIEGO, CA and CALGARY, AB, Nov. 9, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (Oncolytics) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, provided an update on the planned program for pelareorep in pancreatic ductal adenocarcinoma (PDAC).

Key Points: 
  • SAN DIEGO, CA and CALGARY, AB, Nov. 9, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (Oncolytics) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, provided an update on the planned program for pelareorep in pancreatic ductal adenocarcinoma (PDAC).
  • Oncolytics' collaborator, The Pancreatic Cancer Action Network (PanCAN), a pancreatic cancer patient advocacy organization, advised the company that it is implementing a strategic re-evaluation of the Precision PromiseSM program and will not be adding any new investigational therapies to the platform until the re-evaluation is complete.
  • Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics, said, "Oncolytics remains steadfast in its commitment to initiate the Phase 3 program for pelareorep, starting in PDAC, in 2024.
  • Having a compelling Phase 2 dataset in hand and strong connections with the pancreatic cancer community, Oncolytics is well positioned to effectively conduct the Phase 3 pancreatic cancer program.

Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep

Retrieved on: 
Thursday, November 9, 2023
Therapy, Precision, US, Pancreatic Cancer Action Network, Data, FOLFIRINOX, AB, Pancreatic cancer, Hand, Cancer, ONC, Patient, TSX, SAN, Pharmaceutical industry, Oncolytics Biotech, Pelareorep, PDAC

SAN DIEGO, CA and CALGARY, AB, Nov. 9, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (Oncolytics) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, provided an update on the planned program for pelareorep in pancreatic ductal adenocarcinoma (PDAC).

Key Points: 
  • SAN DIEGO, CA and CALGARY, AB, Nov. 9, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (Oncolytics) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, provided an update on the planned program for pelareorep in pancreatic ductal adenocarcinoma (PDAC).
  • Oncolytics' collaborator, The Pancreatic Cancer Action Network (PanCAN), a pancreatic cancer patient advocacy organization, advised the company that it is implementing a strategic re-evaluation of the Precision PromiseSM program and will not be adding any new investigational therapies to the platform until the re-evaluation is complete.
  • Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics, said, "Oncolytics remains steadfast in its commitment to initiate the Phase 3 program for pelareorep, starting in PDAC, in 2024.
  • Having a compelling Phase 2 dataset in hand and strong connections with the pancreatic cancer community, Oncolytics is well positioned to effectively conduct the Phase 3 pancreatic cancer program.